Ragweed pollen hypersensitivity - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Ragweed pollen hypersensitivity - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Ragweed pollen hypersensitivity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ragweed pollen hypersensitivity: Overview
While many people regard spring as prime pollen season, one type of pollen wreaks havoc in the late summer and fall. Ragweed pollen usually reaches peak levels in mid-September; this type of pollen can cause seasonal allergic rhinitis (more commonly known as hay fever), which affects as many as 23 million people in the U.S. Symptoms of ragweed allergy are similar to those of other pollen allergies: Sneezing, Runny nose, Nasal congestion, Headaches, Irritated eyes, Itchy throat. Ragweed pollen can also aggravate asthma symptoms, leading to increased coughing and wheezing. Ragweed allergies can be treated with antihistamines and other allergy medications.
'Ragweed pollen hypersensitivity - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ragweed pollen hypersensitivity pipeline landscape is provided which includes the disease overview and Ragweed pollen hypersensitivity treatment guidelines. The assessment part of the report embraces, in depth Ragweed pollen hypersensitivity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ragweed pollen hypersensitivity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ragweed pollen hypersensitivity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ragweed pollen hypersensitivity Emerging Drugs
Further product details are provided in the report.
Ragweed pollen hypersensitivity: Therapeutic Assessment
This segment of the report provides insights about the different Ragweed pollen hypersensitivity drugs segregated based on following parameters that define the scope of the report, such as:
Ragweed pollen hypersensitivity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ragweed pollen hypersensitivity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ragweed pollen hypersensitivity drugs.
Ragweed pollen hypersensitivity Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Ragweed pollen hypersensitivity - Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Ragweed pollen hypersensitivity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ragweed pollen hypersensitivity: Overview
While many people regard spring as prime pollen season, one type of pollen wreaks havoc in the late summer and fall. Ragweed pollen usually reaches peak levels in mid-September; this type of pollen can cause seasonal allergic rhinitis (more commonly known as hay fever), which affects as many as 23 million people in the U.S. Symptoms of ragweed allergy are similar to those of other pollen allergies: Sneezing, Runny nose, Nasal congestion, Headaches, Irritated eyes, Itchy throat. Ragweed pollen can also aggravate asthma symptoms, leading to increased coughing and wheezing. Ragweed allergies can be treated with antihistamines and other allergy medications.
'Ragweed pollen hypersensitivity - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ragweed pollen hypersensitivity pipeline landscape is provided which includes the disease overview and Ragweed pollen hypersensitivity treatment guidelines. The assessment part of the report embraces, in depth Ragweed pollen hypersensitivity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ragweed pollen hypersensitivity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ragweed pollen hypersensitivity R&D. The therapies under development are focused on novel approaches to treat/improve Ragweed pollen hypersensitivity.
This segment of the Ragweed pollen hypersensitivity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ragweed pollen hypersensitivity Emerging Drugs
- Ragweed MATA MPL: Allergy Therapeutics
- rag-ASIT+™: ASIT biotech
Further product details are provided in the report.
Ragweed pollen hypersensitivity: Therapeutic Assessment
This segment of the report provides insights about the different Ragweed pollen hypersensitivity drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ragweed pollen hypersensitivity
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Ragweed pollen hypersensitivity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ragweed pollen hypersensitivity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ragweed pollen hypersensitivity drugs.
Ragweed pollen hypersensitivity Report Insights
- Ragweed pollen hypersensitivity Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ragweed pollen hypersensitivity drugs?
- How many Ragweed pollen hypersensitivity drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ragweed pollen hypersensitivity?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ragweed pollen hypersensitivity therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ragweed pollen hypersensitivity and their status?
- What are the key designations that have been granted to the emerging drugs?
- HAL Allergy
- ASIT biotech
- Allergy Therapeutics
- Anergis
- rag-ASIT+™
- Ragweed MATA MPL
- AllerDM
Introduction
Executive Summary
Ragweed pollen hypersensitivity: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ragweed pollen hypersensitivity – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ragweed MATA MPL: Allergy Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
rag-ASIT+™: ASIT biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Ragweed pollen hypersensitivity Key Companies
Ragweed pollen hypersensitivity Key Products
Ragweed pollen hypersensitivity- Unmet Needs
Ragweed pollen hypersensitivity- Market Drivers and Barriers
Ragweed pollen hypersensitivity- Future Perspectives and Conclusion
Ragweed pollen hypersensitivity Analyst Views
Ragweed pollen hypersensitivity Key Companies
Appendix
Executive Summary
Ragweed pollen hypersensitivity: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ragweed pollen hypersensitivity – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ragweed MATA MPL: Allergy Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical and Discovery Stage Products
Comparative Analysis
rag-ASIT+™: ASIT biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Ragweed pollen hypersensitivity Key Companies
Ragweed pollen hypersensitivity Key Products
Ragweed pollen hypersensitivity- Unmet Needs
Ragweed pollen hypersensitivity- Market Drivers and Barriers
Ragweed pollen hypersensitivity- Future Perspectives and Conclusion
Ragweed pollen hypersensitivity Analyst Views
Ragweed pollen hypersensitivity Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ragweed pollen hypersensitivity
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ragweed pollen hypersensitivity
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ragweed pollen hypersensitivity
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ragweed pollen hypersensitivity
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products